Gainers
Losers
Spotify closed the session's best performer at 5.24%, taking the stock to $513.73. GoPro, MicroStrategy, Iren, Applied Optoelectronics and Lucid all shed more than 6%.
Latest Activity
Gainers
Losers
Nearly 29 points of spread separated the top and bottom of the board at Monday's close, with Ciena up 14.29% to $445.37 and Tempus AI down 14.21% to $71.68. Four of the five leaders sit in AI infrastructure names.
Now Chief Operating Officer at Moderna, Inc.
Moderna put manufacturing veteran Juan Andres back in an operating seat as Jerh Collins retires, and the market read it as a launch-readiness move: the stock rose 5.71% on Oct. 5. For an $81.1 billion vaccine maker whose next act depends on getting new products out the door, who runs operations is the whole story.
19stocks hit new 52-week highs this week
- HPEHewlett Packard Enterprise$69.33+9.2%
- ASXASE Technology Holding$47.45+5.0%
- AMCAMC Entertainment$2.77+4.4%
- MRNAModerna$190.01+4.4%
- SSentinelOne$25.06+4.0%
- LITELumentum$1,085.42+3.1%
- KEYSKeysight Technologies$384.64+3.0%
- CRWDCrowdStrike$270.04+2.9%
- RBRKRubrik$118.58+2.6%
- PANWPalo Alto Networks$403.24+1.8%
Nineteen stocks cleared fresh 52-week highs this week, and Hewlett Packard Enterprise led the pack by topping its prior peak by 9.2% at $69.33. ASE Technology, AMC, Moderna and a cluster of security names including CrowdStrike and Palo Alto Networks also broke out.
Gainers
Losers
The tape spread nearly 12 points wide at the close: C3.ai finished up 6.43% at $11.01 while Moderna gave back 5.52%. Enterprise tech names took the top four gainer slots, and the losers skew toward high-beta momentum.
Gainers
Losers
Moderna is the session's widest move at the open, off 7.34% to $188.54, while Hewlett Packard Enterprise leads the upside at +6.27%. The gainer list skews toward AI infrastructure names; the losers span biotech, power and defense.
- BRK.BBerkshire Hathaway Inc. New Common Stock (BRK.B)Buy$1K – $15KAug 7
- CBUBS IRA Account Chubb Limited Common Stock (CB)Sell$15K – $50KAug 19
- IBMUBS Brokerage Account International Business Machines Corporation Common Stock (Partial sell$1K – $15KAug 24
- IBMUBS Brokerage Account International Business Machines Corporation Common Stock (Partial sell$1K – $15KAug 24
- MRKUBS IRA Account Merck & Company, Inc. Common Stock (MRK)Buy$15K – $50KAug 19
- MRKUBS IRA Account Merck & Company, Inc. Common Stock (MRK)Buy$15K – $50KAug 19
- MRNAUBS Brokerage Account Moderna, Inc. - Common Stock (MRNA)Partial sell$1K – $15KAug 19
- MRNAUBS Brokerage Account Moderna, Inc. - Common Stock (MRNA)Buy$1K – $15KAug 19
+ 4 more trades in this filing
Made public 33 days after the earliest trade
Salazar rotated out of insurance and legacy tech and into big pharma, with two Merck buys of up to $50,000 each landing the same August day she sold Chubb. The filing also shows private SpaceX shares bought in two separate accounts, a reminder that members are accessing pre-IPO names retail investors cannot touch. Disclosed 33 days after the trades.
MRNA Coverage
7:30am ET
Investing
3 Stocks That Have More Than Doubled the S&P 500’s Return This Year
Three stocks left the S&P 500's 2025 return in the dust, but gains that large raise one uncomfortable question: is the opportunity already gone, or does one of them still have a…
3:03pm ET
Investing
Moderna Is Up 545% in 2026: Take Profits Now, or Keep Buying?
Moderna stock has turned a handful of patient shareholders into believers, but a gain this size forces a choice that most investors never plan for in advance. The pipeline promise is real,…
9:56am ET
Investing
Novavax Pulls Back From Plague-Scare Spike as Officials Call Risk Low; Moderna and Pfizer Inch Higher
A plague headline out of Siberia lifted vaccine stocks, and the agencies closest to the case have since described the risk as low. That reversal in sentiment lands hardest on Novavax (NASDAQ:NVAX),…
9:10am ET
Investing
The $110 Billion Paramount-Warner Merger Closes Today. What Shareholders Need to Know
One group of shareholders walks away with cash at closing. The other inherits a renamed company on a new exchange carrying roughly $80 billion in debt, and the settlement terms make the…
3:02pm ET
Investing
Novavax Soars 22% as Sanofi Carries Nuvaxovid Into Vaccination Season; Moderna Climbs 8%, BioNTech Ticks Up
Sanofi just handed Novavax a commercial lifeline for the fall vaccination season, and the stock is reacting in a way that leaves Moderna and BioNTech looking like bystanders. The real question is…
2:47pm ET
Investing
Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips
Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are trading as though the company’s messenger RNA (mRNA) cancer vaccine has already cleared its final test, even though the complete Phase 3 dataset…
11:00am ET
Investing
Moderna Climbs 3% Despite Citigroup’s Downgrade to Sell; BioNTech Inches Higher, Pfizer Treads Water
Buyers are stepping into Moderna (NASDAQ:MRNA | MRNA Price Prediction) shares, evidently. The move comes one session after a Citigroup (NYSE:C) downgrade to Sell, a sign the market still prizes the company’s…
9:42am ET
Investing
Moderna Sinks 6% on Citi Downgrade; Merck and Pfizer Stay Flat
Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is drawing attention Wednesday after Citigroup downgraded the biotech company to Sell from Hold, arguing that the recent rally has pushed the valuation well ahead…
8:02am ET
Investing
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Ally Financial, BankUnited, Ciena Corporation, CoreWeave, Dow, FormFactor, Lumentum Holdings, Moderna, Target, and More
Rising Treasury yields are rattling markets heading into the final trading day of Q3, and Wall Street analysts are making bold moves on a wide range of stocks from big-box retail to…
10:51am ET
Investing
Moderna Adds Another 5% and Is Up 500% in 2026. Can MRNA Stock Continue the Melt-Up?
Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are rallying again as investors position ahead of a late-October data drop that could validate the first personalized cancer therapy tested at scale. Moderna…
11:45am ET
Investing
Moderna Surges 9% as Phase 3 Melanoma Data Wins Presidential Symposium Slot; Merck and BioNTech Edge Higher
Moderna (NASDAQ:MRNA | MRNA Price Prediction) shares are surging Monday morning after the company announced that its Phase 3 adjuvant melanoma study for intismeran autogene, an investigational messenger RNA individualized neoantigen therapy,…
9:50am ET
Investing
Moderna Climbs 6% as Cancer Vaccine Trade Extends a 137% Month; BioNTech and Novavax Edge Higher
Cancer vaccine momentum is doing the work for Moderna (NASDAQ:MRNA | MRNA Price Prediction) once again on Thursday, extending one of the sharpest one-month runs in large-cap biotech this year without a…
11:56am ET
Investing
Moderna Rallies 8% on 2026 Melt-Up Momentum Even While BioNTech and Merck Stay Flat
Moderna just surged 8% on a morning when its closest cancer-vaccine peer barely budged and its own pipeline partner slipped into the red, and no announcement, trial readout, or analyst call explains…
8:05am ET
Investing
Here Are Thursday’s Top Wall Street Analyst Research Calls: Broadcom, Deere & Company, Dell Technologies, Devon Energy, Moderna, Permian Resources, PG&E, Thermo Fisher, Viper Energy, and More
Markets wobble heading into the Labor Day weekend as bond vigilantes push back against Washington, oil stays tense with Middle East strikes escalating, and Wall Street analysts make bold calls on names…
2:00pm ET
Investing
Moderna Rises 6% Despite GSK Moving Rival mRNA Flu Vaccine to Phase III
GSK just handed Moderna's biggest rival program a late-stage green light, yet traders are sending MRNA stock sharply higher. The logic behind that reaction tells you something important about where the real…